HSHisashi Saji

Hisashi Saji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hisashi Saji has a total of 225 co-authors. Here are the top co-authors by number of shared publications:

  • Hideki Marushima

    Department of Thoracic Surgery, St. Marianna University School of Medicine, Kawasaki, Japan

    14 shared publications
  • Haruhiko Nakamura

    Department of Thoracic Surgery, St. Marianna Medical University Hospital, Kawasaki, Kanagawa 216‑8511, Japan

    13 shared publications
  • Hiroki Sakai

    Department of Thoracic Surgery, St. Marianna University School of Medicine, Kawasaki, Japan

    12 shared publications
  • Norihiko Ikeda

    Department of Surgery, Tokyo Medical University Hospital , Tokyo 160-0023

    12 shared publications
  • Koji Kojima

    Department of Thoracic Surgery, St. Marianna University School of Medicine, Kawasaki, Japan

    11 shared publications
  • Hiroyuki Kimura

    Department of Thoracic Surgery, St. Marianna Medical University Hospital, Kawasaki, Kanagawa 216‑8511, Japan

    10 shared publications

Latest Publications

  • Zone-specific lymph node metastasis prediction model in clinical stage I–II non-small cell lung cancer: a supplementary analysis of JCOG1413

    by Mitsuhiro Isaka, Tomoyuki Hishida, Hisashi Saji, Masashi Wakabayashi, Yasuhisa Ohde, Yasuhiro Tsutani, Makoto Endo, Takahiro Mimae, Tomohiro Miyoshi, Tetsuya Isaka, et al.

  • Open Access

    Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC : Insights From Pathology and Clinical Response to Tarlatamab

    by Shotaro Kaneko, Naoki Furuya, Yoshihisa Sugiura, Hajime Tsuruoka, Kazuhiro Nishiyama, Honoka Morita, Tomoki Okura, Hisashi Saji, Junki Koike, Nobuyuki Ohike, et al.

    Background: Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung neuroendocrine neoplasm with poor prognosis. Recently, DLL3‐targeted bispecific T‐cell engagers (BiTEs) have shown promising efficacy in small cell lung cancer, and clinical trials are ongoing in LCNEC. This study evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy. Methods: We retrospectively reviewed consecutive patients who were diagnosed with LCNEC. Immunohistochemical analyses for DLL3 and CD8 were performed. DLL3 positivity was defined as staining in ≥ 1% of tumor cells. CD8+ TIL infiltration was graded as low, moderate, or high. Results: Among 77 screened LCNEC cases, 44 were eligible for analysis. The median age was 75 years. DLL3 expression was observed in 70.5% of cases and was associated with worse survival. Low CD8+ TIL infiltration was observed in 59.1% of cases. Patients with high CD8+ TIL infiltration demonstrated significantly longer survival than those with low infiltration ( p = 0.03). Among representative clinical cases, a patient with DLL3 (+)/CD8 TILs (−) LCNEC achieved marked tumor shrinkage, whereas a patient with DLL3 (−)/CD8 TILs (−) LCNEC showed no response. Conclusions: DLL3 is frequently expressed in LCNEC and correlates with a poorer prognosis. A majority of LCNEC cases are immunologically characterized as cold tumors lacking CD8+ TILs, which contributes to unfavorable clinical outcomes. Tarlatamab induced a robust antitumor response even in a DLL3 (+) cold tumor. DLL3‐BiTE represents a promising therapeutic strategy for DLL3 (+) LCNEC.

  • Open Access

    Current Status, Clinical Outcomes and Socioeconomic Challenges of Uniportal Video-Assisted Thoracoscopic Surgery in Japan Compared with Robot-Assisted Thoracic Surgery: A Narrative Review

    by Takahiro Homma, Shota Awane, Moeka Tamura, Norifumi Kakizaki, Takayuki Hatakeyama, Kanji Otsubo, Hiroki Sakai, Hideki Marushima, Koji Kojima, Hisashi Saji

    Multiportal video-assisted thoracoscopic surgery (VATS) was introduced in Japan in the 1990s, with uniportal VATS (U-VATS) and robot-assisted thoracic surgery (RATS) following in the 2010s. U-VATS gained significant traction after the 1st Fellowship of the Japanese Association for Chest Surgery (JACS; currently the Japanese Society for Thoracic Surgery, JSTS) in 2018, leading to the establishment of the Japanese Uniportal VATS Interest Group (JUVIG) in April 2018. JUVIG has since driven wider adoption through extensive activities, including educational programs, publications, and collaborative multicenter studies. As a result, expert surgeons now utilize U-VATS for complex procedures such as bronchoplasty, completion lobectomy, complex segmentectomy, and pediatric surgery. Concurrently, RATS gained insurance coverage in Japan in 2018 and has become more prevalent than U-VATS. Despite the significant costs associated with RATS, its adoption rate surpasses that of U-VATS due to institutional policies, perceived ease of implementation, branding, recruitment incentives, and recent national healthcare insurance reimbursement revisions (add-ons) introduced in 2026, which may create administrative pressure to prioritize robotic cases. Although reduced-port RATS is gaining popularity—blurring the lines with U-VATS—and newly emerging indigenous robotic platforms are expected to further accelerate RATS adoption, multiportal VATS (M-VATS) remains the dominant approach in many institutions. Furthermore, maintaining proficiency in VATS, U-VATS, and open thoracotomy remains indispensable for surgical education, economic viability, and acute intraoperative crisis management. Ultimately, while U-VATS represents a promising minimally invasive option, its widespread adoption for major and complex resections in Japan continues to be restricted by both educational and societal barriers.

  • Open Access

    Clinical and Prognostic Significance of Regulator of Chromosome Condensation 1 Expression and Its Complementary Role with Minichromosome Maintenance Protein 2 in Surgically Resected Lung Adenocarcinoma

    by Takayuki Hatakeyama, Hiroki Sakai, Kanji Otsubo, Hiroyuki Kimura, Norifumi Kakizaki, Moeka Tamura, Shota Awane, Takahiro Homma, Hideki Marushima, Koji Kojima, et al.

    Background/Objectives: Regulator of chromosome condensation 1 (RCC1) is a nuclear Ran guanine nucleotide exchange factor involved in nucleocytoplasmic transport, DNA replication, and mitotic regulation. This study investigated the clinical and prognostic significance of RCC1 expression and explored whether RCC1 provides complementary prognostic information to minichromosome maintenance protein 2 (MCM2). Methods: A retrospective, single-institution cohort study was conducted on 75 consecutive patients who underwent complete resection for primary lung adenocarcinoma. Tumor-nuclear RCC1 expression was assessed via immunohistochemistry and quantified as a labeling index (LI) from five intratumoral high-power fields. Results: 19 (25.3%) of 75 patients were classified as having RCC1-high tumors, defined as tumors with an exploratory RCC1 threshold of 60%. RCC1-high tumors were more frequently node-positive (pN1–2: 9/19 vs 9/56). RCC1-high expression (≥60%) was associated with shorter recurrence-free survival (RFS) but not overall survival (OS). RCC1-LI was not independently associated with either RFS or OS. Among the 73 patients with data on both markers, the RCC1-negative/MCM2-negative group (n = 27) had the most favorable RFS and OS patterns. Meanwhile, the RCC1-positive/MCM2-positive group (n = 13) exhibited the least favorable RFS pattern. Conclusions: RCC1 expression was associated with nodal involvement. However, it was not an independent prognostic factor for OS or RFS. Based on an exploratory combined-marker analysis, MCM2 may provide the dominant survival-related prognostic signal. However, RCC1 may offer complementary information regarding aggressive tumor behavior and recurrence. These hypothesis-generating findings must be further validated in larger independent cohorts with standardized and reproducible biomarker quantification.

  • Open Access

    Lobectomy versus segmentectomy for centrally located, small-sized (≤ 2 cm), and radiologically solid-dominant non-small cell lung cancer: a phase III randomized controlled trial (UNLIMITED; JCOG2501)

    by Takeshi Uozumi, Norifumi Tsubokawa, Masashi Wakabayashi, Noriko Mitome, Aritoshi Hattori, Takahiro Mimae, Tomohiro Miyoshi, Tetsuya Isaka, Akira Hamada, Makoto Endo, et al.

    BackgroundSegmentectomy has demonstrated favorable long-term outcomes compared with lobectomy in patients with small peripheral non-small cell lung cancer (NSCLC). However, whether similar benefits can be achieved in centrally located, small-sized, radiologically solid-dominant NSCLC remains uncertain. This study aims to confirm the non-inferiority of segmentectomy to lobectomy within this setting.MethodsJCOG2501 is a multi-institutional, open-label, phase III, randomized controlled trial designed to confirm the non-inferiority of segmentectomy to lobectomy in patients with centrally located (within the inner two-thirds of the lung field), small-sized (maximum tumor diameter ≤2 cm), radiologically solid-dominant (consolidation-to-tumor ratio, >0.5 to ≤1) NSCLC. Eligible patients are aged 18–85 years with an Eastern Cooperative Oncology Group performance status of 0–1 and adequate pulmonary function. A two-step registration system is adopted, with preoperative and intraoperative confirmation of patient eligibility. Following confirmation of eligibility at the second registration, patients are randomized 1:1 to either the lobectomy or segmentectomy arm. In both arms, systematic or lobe-specific lymph node dissection is mandatory, and nodal sampling alone is prohibited. The primary endpoint is overall survival, analyzed in all randomized patients. Assuming a non-inferiority margin of 6.5% for 5-year overall survival, 490 patients are required to achieve 70% power with a one-sided α = 5%. The planned sample size is 500 patients at the second registration. JCOG2501 was initiated in February 2026 and is registered with the Japan Registry of Clinical Trials (jRCT1030250727).ConclusionsJCOG2501 will clarify the role of segmentectomy in centrally located small-sized NSCLC and inform future surgical standards.

  • Open Access

    Current Status and Challenges of Uniportal Video-Assisted Thoracoscopic Surgery in Japan Compared with Robot-Assisted Thoracic Surgery: A Narrative Review

    by Takahiro Homma, Shota Awane, Moeka Tamura, Norifumi Kakizaki, Takayuki Hatakeyama, Kanji Otsubo, Hiroki Sakai, Hideki Marushima, Koji Kojima, Hisashi Saji

    Multiportal video-assisted thoracoscopic surgery (VATS) was introduced in Japan in the 1990s, with uniportal VATS (U-VATS) and robot-assisted thoracic surgery (RATS) following in the 2010s. U-VATS gained significant traction after the 1st Japanese Society of Thoracic Surgeons (JSTS) Fellowship in 2018, leading to the establishment of the Japanese Uniportal VATS Interest Group (JUVIG) in April 2018. JUVIG has since driven wider adoption through extensive activities, including educational programs, publications, and collaborative multicenter studies. As a result, expert surgeons now utilize U-VATS for complex procedures such as bronchoplasty, completion lobectomy, complex segmentectomy, and pediatric surgery. Concurrently, RATS gained insurance coverage in Japan in 2018 and has become more prevalent than U-VATS. Despite the significant costs associated with RATS, its adoption rate surpasses that of U-VATS due to institutional policies, perceived ease of implementation, branding, recruitment incentives, and recent national healthcare insurance reimbursement revisions (add-ons) introduced in 2026, which exert administrative pressure to prioritize robotic cases. Although reduced-port RATS is gaining popularity—blurring the lines with U-VATS—and newly emerging indigenous robotic platforms are expected to further accelerate RATS adoption, multiportal VATS (M-VATS) remains the dominant approach in many institutions. Furthermore, maintaining proficiency in VATS, U-VATS, and open thoracotomy remains indispensable for surgical education, economic viability, and acute intraoperative crisis management. Ultimately, while U-VATS represents a promising minimally invasive option, its widespread adoption for major and complex resections in Japan continues to be restricted by both educational and societal barriers.

  • Open Access

    Surgical Complexity and Perioperative Feasibility Following Neoadjuvant Chemotherapy, Chemoradiotherapy, or Chemoimmunotherapy in Stage II–III Non-Small Cell Lung Cancer: A Retrospective Single-Institution Study

    by Hiroki Sakai, Takayuki Hatakeyama, Takahiro Homma, Kanji Otsubo, Norifumi Kakizaki, Hideki Marushima, Koji Kojima, Kei Morikawa, Naoki Furuya, Masamichi Mineshita, et al.

    Background: Neoadjuvant chemoimmunotherapy has emerged as a standard option for resectable stage II–III non-small cell lung cancer (NSCLC); however, its impact on surgical feasibility, operative complexity, and perioperative outcomes remains incompletely characterized. We compared surgical feasibility, complexity, and perioperative outcomes across different neoadjuvant strategies. Methods: This single-center retrospective study included patients with stage II–III NSCLC who underwent curative-intent resection following neoadjuvant chemoimmunotherapy (neo-CIT), chemotherapy alone (neo-CT), or chemoradiotherapy (neo-CRT) during the same period. Surgical complexity was assessed using a four-level empirical grading scale. Perioperative outcomes, pathological response, and complications were compared among treatment groups using appropriate nonparametric statistical methods. Results: Twenty-four patients were included in the analysis (neo-CIT, n = 8; neo-CT, n = 12; neo-CRT, n = 4). R0 resection was achieved in 100%, 66.7%, and 75% of patients in the neo-CIT, neo-CT, and neo-CRT groups, respectively. Operative time, estimated blood loss, length of hospital stay, and overall postoperative complication rates did not differ significantly among groups. Thirty-day mortality was 0% in all groups, and 90-day mortality was 12.5% in the neo-CIT group and 0% in the neo-CT and neo-CRT groups. Surgical complexity scores were high across all cohorts and, when analyzed across the entire cohort, were not significantly associated with longer operative time (p = 0.16), greater blood loss (p = 0.83), or pathological response (p = 0.55). Neo-CIT was not associated with increased objective perioperative risk compared with neoadjuvant chemotherapy or chemoradiotherapy. Conclusions: In this single-institution exploratory analysis, neoadjuvant chemoimmunotherapy appeared to be surgically feasible and did not result in an apparent increase in perioperative risk compared with other neoadjuvant strategies. Although surgeons perceived increased operative complexity, objective perioperative risk remained acceptable when procedures were performed by experienced thoracic surgeons. However, given the limited sample size and lack of statistical power, these findings should be interpreted with caution and should not be considered evidence of equivalence.

  • Open Access

    Surgical Complexity and Perioperative Feasibility Following Neoadjuvant Chemotherapy, Chemoradiotherapy, or Chemoimmunotherapy in Stage II–III Non-Small Cell Lung Cancer: A Retrospective Single-Institution Study

    by Hiroki Sakai, Takayuki Hatakeyama, Takahiro Homma, Kanji Otsubo, Norifumi Kakizaki, Hideki Marushima, Koji Kojima, Kei Morikawa, Naoki Furuya, Masamichi Mineshita, et al.

    Background: Neoadjuvant chemoimmunotherapy is a standard option for resectable stage II–III non-small cell lung cancer (NSCLC); however, its impact on surgical feasibility, operative complexity, and perioperative outcomes remains incompletely characterized. We compared surgical feasibility, complexity, and perioperative outcomes across different neoadjuvant strategies. Methods: This single-center retrospective study included patients with stage II–III NSCLC who underwent curative-intent resection following neoadjuvant chemoimmunotherapy (neo-CIT), chemotherapy alone (neo-CT), or chemoradiotherapy (neo-CRT) during the same period. Surgical complexity was assessed using a four-level empirical grading scale. Perioperative outcomes, pathological response, and complications were compared among treatment groups using appropriate nonparametric statistical methods. Results: Twenty-four patients were included in the analysis (neo-CIT, n = 8; neo-CT, n = 12; neo-CRT, n = 4). R0 resection was achieved in 100%, 83.3%, and 100% of patients in the neo-CIT, neo-CT, and neo-CRT groups, respectively. Operative time, estimated blood loss, length of hospital stay, and overall postoperative complication rates did not differ significantly among groups. Thirty-day mortality was 0% in all groups, and 90-day mortality was 12.5% in the neo-CIT group and 0% in the neo-CT and neo-CRT groups. Surgical complexity scores were high across all cohorts and, when analyzed across the entire cohort, were not significantly associated with longer operative time (P = 0.16), greater blood loss (P = 0.83), or pathological response (P = 0.55). Neo-CIT was not associated with higher conversion rates or increased objective perioperative risk compared with neoadjuvant chemotherapy or chemoradiotherapy. Conclusions: In this single-institution exploratory analysis, neoadjuvant chemoimmunotherapy appeared to be surgically feasible and did not result in an apparent increase in perioperative risk compared with other neoadjuvant strategies. Although surgeons perceived increased operative complexity, objective perioperative risk remained acceptable when procedures were performed by experienced thoracic surgeons. However, considering the limited sample size and lack of statistical power, these findings should be interpreted with caution and should not be considered evidence of equivalence.

  • Open Access

    Adenoid cystic carcinoma of the thymus: a case report and literature review

    by Shota Awane, Kanji Otsubo, Moeka Tamura, Norifumi Kakizaki, Takayuki Hatakeyama, Hiroki Sakai, Takahiro Homma, Hideki Marushima, Koji Kojima, Hirotaka Koizumi, et al.

    Primary adenoid cystic carcinoma (ACC) of the thymus is extremely rare. Although thymic ACC is generally slow growing, complete surgical resection is essen

  • Open Access

    Oncologic Safety of Omitting Mediastinal Lymph Node Dissection in Segmentectomy for Ground-Glass Opacity-Dominant Lung Cancer: A Supplementary Analysis of JCOG1211

    by Ken Onodera, Keiju Aokage, Hisashi Saji, Masashi Wakabayashi, Makoto Endo, Yasuhiro Tsutani, Kazuo Nakagawa, Yoshihisa Shimada, Tetsuya Isaka, Mitsuhiro Isaka, et al.